Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 16, 2017 - Issue 4
Submit an article Journal homepage
264
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab

Jianhong ZhuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Junyan WuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Guocheng LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Jianfang LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Yin LinGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Zhichao HeGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Chen SuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Wenxia ZhaoGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Qianqian WuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Zepeng ChenGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaView further author information
&
Kaifeng QiuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 423-428 | Received 02 Nov 2016, Accepted 16 Feb 2017, Published online: 24 Feb 2017

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Chunlei Li, Zhengjun Li, Qing Sun, Yanxiao Xiang & Anchang Liu. (2023) Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system. Expert Opinion on Drug Safety 0:0, pages 1-8.
Read now
Siyuan Gao, Mei Zhang, Kaishan Wu, Jianhong Zhu, Zhichao He, Jianfang Li, Chuxiong Chen, Kaifeng Qiu, Xiaoxia Yu & Junyan Wu. (2020) Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opinion on Drug Safety 19:5, pages 617-623.
Read now
Joseph A. Pinto, Luis E. Raez, Helena Oliveres & Christian C. Rolfo. (2019) Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Expert Opinion on Biological Therapy 19:6, pages 509-515.
Read now
Jianhong Zhu, Rifang Liao, Chen Su, Dan Liang, Junyan Wu, Kaifeng Qiu & Jianfang Li. (2018) Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert Review of Anticancer Therapy 18:2, pages 193-198.
Read now

Articles from other publishers (4)

Jianhong Zhu, Guanghui Chen, Zhichao He, Yayuan Zheng, Siyuan Gao, Jianfang Li, Yin Ling, Xiaoxia Yu, Kaifeng Qiu & Junyan Wu. (2021) Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. eClinicalMedicine 37, pages 100951.
Crossref
Zhiwei Wang, Xiao Yang, Jitao Wang, Shuai Wang, Xiaorong Mao, Mingxing Li, Yongzhao Zhao, Weidong Wang, Xiaolong Qi & Tongwei Wu. (2019) Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis. Journal of Cancer Research and Therapeutics 15:7, pages 1435.
Crossref
Jacob Lambdin & Marie Borum. (2018) Toxic Injury to the Gastointestinal Tract After Ipilimumab Therapy. Journal of Osteopathic Medicine 118:8, pages 506-506.
Crossref
Jianhong Zhu, Wenxia Zhao, Dan Liang, Guocheng Li, Kaifeng Qiu, Junyan Wu & Jianfang Li. (2017) Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. International Journal of Clinical Oncology 23:2, pages 389-399.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.